Antitumor Platinum(II) Hybrid Compounds Based on a Glucosylglycerol Scaffold

Platinum(II) drugs such as cisplatin, carboplatin and oxaliplatin are antineoplastic drugs clinically available for the treatment of different kinds of cancers, including ovarian carcinoma. However, their use is limited by the occurrence of severe systemic side effects and resistance [1, 2]. For these reasons, the development of new platinum-based compounds endowed with higher selectivity against cancer cells and able to overcome resistance is an active research field. A promising strategy to pursuit these goals is the design of hybrid platinum(II) compounds bearing bioactive ligands able to selectively target cancer cells, improve the platinum-mediated antitumor activity and/or overcome resistance by interacting with selected targets known for their involvement in cancer resistance [3]. In this context, due to its peculiar structure, 2-O-β-D-glucosylglycerol (a natural compound named Lilioside B) [4] could be efficiently used at the same time as the complexing agent of platinum(II) and as the point of attachment of cancer involved bioactive compounds. Thus, the present communication will show some preliminary results on the synthesis and cytotoxicity data, on ovarian cancer cells, of a water soluble platinum(II) hybrid compound in which, similarly to carboplatin, a properly modified 2-O-β-D-glucosylglycerol is able to complex platinum(II). References 1. Khoury, A.; Deo, K.M.; Aldrich-Wright, J.R. J. Inorg. Biochem., 2020, 207, 111070. 2. Rottenberg, S., Disler, C., & Perego, P. Nature reviews. Cancer, 2021, 21, 37. 3. Zuccolo, M,; Arrighetti, N.; Perego, P.; Colombo, D. Curr. Med. Chem., 2022, 29, 2566. 4. Kaneda, M.; Mizutani, K.; Takahashi, Y.; Kurono, G.; Nishikawa, Y. Tetrahedron Lett., 1974, 15, 3937.